Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions

Head and Neck

Volumn 26, Issue 11, 2004, Pages 960-966

  Oestreicher Kedem, Yael ^a,b   Halpern, Marisa ^a,b   Roizman, Pepi ^a,b   Hardy, Britta ^b   Sulkes, Jaqueline ^b,c   Feinmesser, Raphael ^a,b   Stern, Yoram ^a,b  

^a Beilinson Campus ^*  (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

Author keywords

Adenoma; Carcinoma; Follicular patterned lesions; Galectin 3; Thyroid

Indexed keywords

GALECTIN 3; TUMOR MARKER;

ARTICLE; BENIGN TUMOR; CANCER INVASION; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; ONCOCYTOMA; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THYROID ADENOMA; THYROID FOLLICULAR CARCINOMA; TISSUE LEVEL;

ADENOCARCINOMA, FOLLICULAR; ADENOMA, OXYPHILIC; CARCINOMA, PAPILLARY, FOLLICULAR; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 8444238666     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.20087     Document Type: Article

References (35)

1. Baloch ZB, LiVolsi VA. Follicular-patterned lesions of the thyroid. The bane of the pathologist. Am J Clin Pathol 2002;17:143-150.
2. Xu XC, El-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 1995;147:815-822.
3. Gasbarri A, Martegani MP, Del Prete F, et al. Galectin 3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol 1999;17:3495-3502.
4. Amrikachi M, Ramzy I, Rubenfeld S, Wheeler TM. Accuracy of fine-needle aspiration of thyroid, a review of 6226 cases and correlation with surgical or clinical outcome. Arch Pathol Lab Med 2001;125:484-488.
5. Goodell WM, Saboorian MH, Ashfaq R. Fine-needle aspiration diagnosis of the follicular variant of papillary carcinoma. Cancer 1998;84:349-354.
6. Tielens ET, Sherman SI, Hruban RH, Ladenson PW. Follicular variant of papillary thyroid carcinoma. A clinico-pathological study. Cancer 1994;73:424-431.
7. Lin HS, Komisar A, Opher H, Blaugrund SM. Follicular variant of papillary carcinoma: the diagnostic limitations of preoperative fine-needle aspiration and intraoperative frozen section evaluation. Laryngoscope 2000;110:1432-1436.
8. Franssila KO, Ackerman LV, Brown CL, et al. Follicular carcinoma. Semin Diagn Pathol 1985;2:101-122.
9. Fonseca E, Sobrinho-Simoes M. Diagnostic problems in differentiated carcinoma of the thyroid. Pathol Res Pract 1995;191:318-331.
10. Kawachi K, Matsushita Y, Yonezawa S, et al. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 2000;31:428-433.
11. Choufani G, Nagy N, Sauissez S, et al. The levels of expression of galactin-1, galactin-3 and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. Cancer 1999;86:2353-2363.
12. Glinsky VV, Glinsky GV, Rittenhouse-Olson K, et al. The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res 2001;61:4851-4857.
13. Gabius HJ. Animal lectins. Eur J Biochem 1997;243:543-576.
14. Matarrese P, Fusco O, Tinari N, et al. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 2000;85:545-554.
15. Le Marer N, Hughes RC. Effects of the carbohydrate-binding protein galectin-3 on the invasiveness of human breast carcinoma cells. J Cell Physiol 1996;168:51-58.
16. Bartolazzi A, Gasbarri A, Papotti M, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001;357:1644-1650.
17. Inohara H, Honjo Y, Yoshii T, et al. Expression of galectin-3 in fine needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 1999;85:2475-2484.
18. Orlandi F, Saggiorato E, Piavano G, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 1998;58:3015-3020.
19. Naish SJ, editor. Handbook - Immunochemical staining methods. Carpinteria: DAKO Corporation; 1989.
20. van Den Brule FA, Waltregny D, Liu FT, Castronovo V. Alterations of the cytoplasmatic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 2000;89:361-367.
21. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-651.
22. Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcik EM, Baloch ZW. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med 2002;126:710-713.
23. Lotan R, Matsushita Y, Ohanessian D, et al. Lactose-binding lectin expression in human colorectal carcinomas: relation to tumor progression. Carbohydrate Res 1991;213:47-57.
24. Bresalier RS, Yan PS, Byrd JC, et al. Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the nervous system. Cancer 1998;80:776-797.
25. Inohara H, Akahani S, Koths K, Raz A. Interaction between galectin-3 and mac-2-binding protein mediates cell-cell adhesion. Cancer Res 1996;56:4530-4534.
26. Bresalier RS, Mazurek N, Sternberg LR, et al. Metastasis of human colon cancer is altered by modifying expression of the beta-galactose-binding protein galectin-3. Gastroenterology 1998;115:287-296.
27. van den Brule FA, Price J, Sobel ME, et al. Inverse expression of two laminin binding proteins, 67LR and galectin-3, correlates with the invasive phenotype of trophoblastic tissue. Biochem Biophys Res Commun 1994;201:388-393.
28. Song YK, Billiar TR, Lee YJ. Role of galectin-3 in breast cancer metastasis. Involvement of nitric oxide. Am J Pathol 2002;160:1069-1075.
29. Iurisci I, Inari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 2000;4:1389-1393.
30. Beesley MF, McKlaren KM. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology 2002;41:236-243.
31. Martins L, Matsou SE, Ebina KN, Kulcsar MAV, Friguglietti CUM, Kinura ET. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J Clin Endocrinol 2002;87:4806-4810.
32. Coli A, Bigotti G, Zucchetti F, Begro F, Massi G. Galectin-3, a marker of well differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology 2002;40:80-87.
33. Nascimento MCPA, Bisi H, Alves VAF, Longatto-Filho A, Kanamura CT, Mederios-Neto G. Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas. Clin Res 2001;12:275-279.
34. Bernet VJ, Anderson J, Viashnav Y, et al. Determination of galectin-3 messenger ribonucleic acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol 2002;87:4792-4796.
35. Lloyd RV. Distinguishing benign from malignant thyroid lesions: galectin-3 as the latest candidate. Endocrine Pathol 2001;3:255-257.